Loading...
XJPX
4978
Market cap112mUSD
May 20, Last price  
172.00JPY
1D
12.42%
1Q
-16.10%
Jan 2017
-60.00%
IPO
-95.30%
Name

ReproCell Inc

Chart & Performance

D1W1MN
XJPX:4978 chart
P/E
—
P/S
6.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.59%
Rev. gr., 5y
17.39%
Revenues
2.43b
-17.83%
316,524,000420,077,000460,950,000567,001,0001,066,373,0001,257,812,000926,255,0001,088,527,0001,199,908,0001,286,283,0002,234,568,0002,953,271,0002,426,817,000
Net income
-31m
L-89.71%
-22,206,0005,869,000-133,923,000-451,793,000-1,961,351,000-911,664,000-2,172,046,000-601,424,000-1,016,520,000-812,572,000-575,094,000-305,313,000-31,415,000
CFO
-11m
L-91.85%
-13,076,000-375,000-39,042,000-626,798,000-614,376,000-775,025,000-636,720,000-554,831,000-689,803,000-648,883,000-246,244,000-140,534,000-11,451,000

Profile

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
URL
https://reprocell.co.jp/
IPO date
Jun 26, 2013
Employees
92
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
2,426,817
-17.83%
2,953,271
32.16%
Cost of revenue
2,836,265
3,309,495
Unusual Expense (Income)
NOPBT
(409,448)
(356,224)
NOPBT Margin
Operating Taxes
2,544
1,650
Tax Rate
NOPAT
(411,992)
(357,874)
Net income
(31,415)
-89.71%
(305,313)
-46.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
538,750
562,872
BB yield
-3.96%
-2.77%
Debt
Debt current
(107,806)
Long-term debt
Deferred revenue
Other long-term liabilities
8,969
7,754
Net debt
(7,948,778)
(7,544,220)
Cash flow
Cash from operating activities
(11,451)
(140,534)
CAPEX
(192,433)
(161,032)
Cash from investing activities
404,424
(1,087,496)
Cash from financing activities
544,050
482,872
FCF
(691,616)
(361,300)
Balance
Cash
6,566,857
6,379,414
Long term investments
1,381,921
1,057,000
Excess cash
7,827,437
7,288,750
Stockholders' equity
1,775,323
1,508,310
Invested Capital
6,545,241
5,940,212
ROIC
ROCE
EV
Common stock shares outstanding
85,620
84,230
Price
159.00
-34.02%
241.00
6.17%
Market cap
13,613,580
-32.94%
20,299,430
17.74%
EV
5,664,802
12,769,035
EBITDA
(372,335)
(307,230)
EV/EBITDA
Interest
80
Interest/NOPBT